Business Description
Jiangsu Nhwa Pharmaceutical Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100000CG8
Share Class Description:
SZSE:002262: Class ACompare
Compare
Traded in other countries / regions
002262.China IPO Date
2008-07-23Description
Jiangsu Nhwa Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in manufacturing of APIs and dosages.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 25.34 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.11 | |||||
| Interest Coverage | 298.32 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 19.35 | |||||
| Beneish M-Score | -2.24 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.7 | |||||
| 3-Year EBITDA Growth Rate | 12.3 | |||||
| 3-Year EPS without NRI Growth Rate | 13 | |||||
| 3-Year FCF Growth Rate | -13.3 | |||||
| 3-Year Book Growth Rate | 16 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 19.69 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 18.17 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 82.59 | |||||
| 9-Day RSI | 72.09 | |||||
| 14-Day RSI | 66.1 | |||||
| 6-1 Month Momentum % | 13.71 | |||||
| 12-1 Month Momentum % | -3.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.62 | |||||
| Quick Ratio | 5.95 | |||||
| Cash Ratio | 4.25 | |||||
| Days Inventory | 153.23 | |||||
| Days Sales Outstanding | 71.47 | |||||
| Days Payable | 73.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.17 | |||||
| Dividend Payout Ratio | 0.28 | |||||
| 3-Year Dividend Growth Rate | 26 | |||||
| Forward Dividend Yield % | 1.17 | |||||
| 5-Year Yield-on-Cost % | 5.29 | |||||
| Shareholder Yield % | 1.21 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 72.25 | |||||
| Operating Margin % | 23.33 | |||||
| Net Margin % | 20.74 | |||||
| FCF Margin % | 13.92 | |||||
| ROE % | 17.44 | |||||
| ROA % | 15.34 | |||||
| ROIC % | 34.95 | |||||
| 3-Year ROIIC % | 30.18 | |||||
| ROC (Joel Greenblatt) % | 52.66 | |||||
| ROCE % | 19.58 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.55 | |||||
| Forward PE Ratio | 18.92 | |||||
| PE Ratio without NRI | 23.74 | |||||
| Shiller PE Ratio | 41.92 | |||||
| Price-to-Owner-Earnings | 31.27 | |||||
| PEG Ratio | 1.9 | |||||
| PS Ratio | 5.1 | |||||
| PB Ratio | 4.07 | |||||
| Price-to-Tangible-Book | 4.26 | |||||
| Price-to-Free-Cash-Flow | 36.54 | |||||
| Price-to-Operating-Cash-Flow | 23.22 | |||||
| EV-to-EBIT | 17.31 | |||||
| EV-to-EBITDA | 17.31 | |||||
| EV-to-Revenue | 4.07 | |||||
| EV-to-FCF | 29.28 | |||||
| Price-to-Projected-FCF | 2.3 | |||||
| Price-to-DCF (Earnings Based) | 0.73 | |||||
| Price-to-DCF (FCF Based) | 1.06 | |||||
| Price-to-Median-PS-Value | 1.16 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.18 | |||||
| Price-to-Graham-Number | 2.12 | |||||
| Price-to-Net-Current-Asset-Value | 5.99 | |||||
| Price-to-Net-Cash | 10.48 | |||||
| Earnings Yield (Greenblatt) % | 5.78 | |||||
| FCF Yield % | 2.72 | |||||
| Forward Rate of Return (Yacktman) % | 13.22 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jiangsu Nhwa Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 5,404.573 | ||
| EPS (TTM) (Â¥) | 1.11 | ||
| Beta | 0.09 | ||
| Volatility % | 27.34 | ||
| 14-Day RSI | 66.1 | ||
| 14-Day ATR (Â¥) | 0.952 | ||
| 20-Day SMA (Â¥) | 25.1845 | ||
| 12-1 Month Momentum % | -3.92 | ||
| 52-Week Range (Â¥) | 20.64 - 28.76 | ||
| Shares Outstanding (Mil) | 1,016.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jiangsu Nhwa Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jiangsu Nhwa Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Jiangsu Nhwa Pharmaceutical Co Ltd Frequently Asked Questions
What is Jiangsu Nhwa Pharmaceutical Co Ltd(SZSE:002262)'s stock price today?
The current price of SZSE:002262 is ¥27.25. The 52 week high of SZSE:002262 is ¥28.76 and 52 week low is ¥20.64.
When is next earnings date of Jiangsu Nhwa Pharmaceutical Co Ltd(SZSE:002262)?
The next earnings date of Jiangsu Nhwa Pharmaceutical Co Ltd(SZSE:002262) is .
Does Jiangsu Nhwa Pharmaceutical Co Ltd(SZSE:002262) pay dividends? If so, how much?
The Dividend Yield %  of Jiangsu Nhwa Pharmaceutical Co Ltd(SZSE:002262) is 1.17% (As of Today), Highest Dividend Payout Ratio of Jiangsu Nhwa Pharmaceutical Co Ltd(SZSE:002262) was 0.28. The lowest was 0.08. And the median was 0.11. The  Forward Dividend Yield % of Jiangsu Nhwa Pharmaceutical Co Ltd(SZSE:002262) is 1.17%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers